Camicinal
Appearance
Clinical data | |
---|---|
Other names | GSK962040 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.158.139 |
Chemical and physical data | |
Formula | C25H33FN4O |
Molar mass | 424.564 g·mol−1 |
3D model (JSmol) | |
| |
|
Camicinal is a motilin agonist for the treatment of gastroparesis.[1][2][3]
References
- ^ Barshop K, Kuo B (January 2015). "The investigational drug camicinal for the treatment of gastroparesis". Expert Opinion on Investigational Drugs. 24 (1): 133–140. doi:10.1517/13543784.2015.975792. PMID 25341626. S2CID 25896703.
- ^ Hobson R, Farmer AD, Dewit OE, O'Donnell M, Hacquoil K, Robertson D, et al. (November 2015). "The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial". Neurogastroenterology and Motility. 27 (11): 1629–37. doi:10.1111/nmo.12663. PMID 26348542.
- ^ Chapman MJ, Deane AM, O'Connor SL, Nguyen NQ, Fraser RJ, Richards DB, et al. (August 2016). "The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial". Critical Care. 20 (1): 232. doi:10.1186/s13054-016-1420-4. PMC 4967996. PMID 27476581.
{{cite journal}}
: CS1 maint: unflagged free DOI (link)